- Home
- FDBC vs PVLA Comparison
FDBC vs PVLA Comparison
Compare FDBC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDBC
- PVLA
- Stock Information
- Founded
- FDBC 1902
- PVLA 2015
- Country
- FDBC United States
- PVLA United States
- Employees
- FDBC N/A
- PVLA N/A
- Industry
- FDBC Major Banks
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- FDBC Finance
- PVLA Health Care
- Exchange
- FDBC Nasdaq
- PVLA Nasdaq
- Market Cap
- FDBC 226.2M
- PVLA 253.2M
- IPO Year
- FDBC N/A
- PVLA N/A
- Fundamental
- Price
- FDBC $41.26
- PVLA $24.41
- Analyst Decision
- FDBC
- PVLA Strong Buy
- Analyst Count
- FDBC 0
- PVLA 7
- Target Price
- FDBC N/A
- PVLA $46.29
- AVG Volume (30 Days)
- FDBC 5.7K
- PVLA 56.0K
- Earning Date
- FDBC 07-23-2025
- PVLA 05-15-2025
- Dividend Yield
- FDBC 3.85%
- PVLA N/A
- EPS Growth
- FDBC 32.34
- PVLA N/A
- EPS
- FDBC 3.75
- PVLA N/A
- Revenue
- FDBC $81,316,000.00
- PVLA N/A
- Revenue This Year
- FDBC N/A
- PVLA N/A
- Revenue Next Year
- FDBC N/A
- PVLA N/A
- P/E Ratio
- FDBC $10.60
- PVLA N/A
- Revenue Growth
- FDBC 15.07
- PVLA N/A
- 52 Week Low
- FDBC $37.00
- PVLA $11.17
- 52 Week High
- FDBC $61.21
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- FDBC 51.08
- PVLA N/A
- Support Level
- FDBC $39.39
- PVLA N/A
- Resistance Level
- FDBC $41.21
- PVLA N/A
- Average True Range (ATR)
- FDBC 1.19
- PVLA 0.00
- MACD
- FDBC -0.10
- PVLA 0.00
- Stochastic Oscillator
- FDBC 46.33
- PVLA 0.00
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.